Experimental drug BL-M08D1 takes on recurrent lymphoid cancers
NCT ID NCT06718634
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing an experimental drug called BL-M08D1 in 22 adults with relapsed or refractory lymphoid malignancies (cancers of the lymph system that have come back or not responded to treatment). The drug is given by IV every 3 weeks. The main goals are to check safety, find the right dose, and get a first look at whether it might help shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BL-M08D1 (an experimental drug given by IV infusion every 3 weeks)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat lymphoid cancers that have come back or not responded to standard therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 22 participants, so the main goal is safety and dosing, not proof of effectiveness. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LYMPHOID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, China